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Airway Remodeling in Asthma and
Irreversible Airflow Limitation
―ECM Deposition in Airway and
Possible Therapy for Remodeling―
Kohei Yamauchi1 and Hiroshi Inoue1
ABSTRACT
Airway remodeling in asthma is characterized by goblet cell hyperplasia, subepithelial fibrosis, and hyperplasia
and hypertrophy of airway smooth muscle cells. The airway wall thickness increases because of subepithelial
fibrosis, and hyperplasia and hypertrophy of the airway smooth muscle cells and submucosal glands. Airway
remodeling, therefore, can often cause irreversible airflow limitation and an increase of airway hyperrespon-
siveness. Recent studies have described the molecular and cellular mechanisms of collagen deposition in the
airway wall such as subepithelial fibrosis. Fibroblasts or myofibroblasts play a critical role in the exaggerated
deposition of collagen in asthmatic airways. Bone marrow derived fibroblasts may play a role in fibrotic remod-
eling in asthmatic airways. Airway remodeling is induced by cytokines and mediators produced in chronic aller-
gic airway inflammation. Since, once formed, remodeling is resistant to asthma therapy, early intervention with
inhaled corticosteroid should be considered to prevent the progress of airway remodeling.
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INTRODUCTION
Bronchial asthma has been recognized as a respira-
tory disease that causes a long term decline of the
lung function. As an obstructive lung disease, COPD
is also widely recognized to cause a long term decline
of the lung function including irreversible airflow
limitation. As with COPD, reversible airflow limita-
tion is a characteristic physiological feature of bron-
chial asthma. It had been thought that the impair-
ment of pulmonary function in asthma could be re-
versed to a normal level with sufficient therapy. How-
ever, since inhaled corticosteroid therapy was intro-
duced globally at the end of the last century, many
clinicians noticed that the airflow limitation remained
in some asthmatics after the administration of oral
corticosteroid, high dose inhaled corticosteroid and
bronchodilators.
Peat et al. and Lange et al. reported that FEV1 in
asthmatics declined faster than in normal individuals
(Fig. 1).1,2 These airflow limitations are thought to re-
sult mainly from airway remodeling. In particular, fi-
brosis of the airway wall has been thought to play a
major role in the irreversible airflow limitation in both
asthma and COPD.
In this review, we describe the effects of airway re-
modeling on pulmonary function and the asthma se-
verity, and the cellular mechanism of airway fibrosis
in asthma.
AIRWAY REMODELING IN ASTHMATIC AIR-
WAY
Since long before, pathological analyses have re-
vealed the dramatic structural changes in airways in
autopsies of patients with severe asthma.3,4 Such
changes are transformation of the epithelium to gob-
let cells, thickening of the epithelial basement mem-
brane, deposition of extracellular matrix in the
subepithelial layer, hyperplasia of submucosal
glands, hypertrophy and hyperplasia of bronchial
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Fig. 1 The impairment of pulmonary function in asthma. 
Decrease of FEV1 in asthma was faster compared to that in 
normal individuals. (This figure was from Ref 1, and 
modified.)
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smooth muscle, and an increase of submucosal ves-
sels.5 These structural findings are characteristic for
asthma and are referred to as airway remodeling.
From the view point of lung function, there have
been reports since the 1970’s describing patients with
chronic asthma who exhibited persistent airflow limi-
tation even during periods of complete remission or
despite treatment with bronchodilators, including
theophylline and β2 stimulants, and oral corticoster-
oids.6 Persistent airflow limitation is not rare in pa-
tients with moderatesevere asthma during asynpto-
matic periods after the use of β2 stimulants and there
are many difficult asthmatics among these patients.
Their airflow limitation is not fully improved by a
high dose of corticosteroid, suggesting that the air-
flow limitation is not caused by transient airway in-
flammation.7 Airway remodeling results in thickening
of the airway wall and was thought to cause irrevers-
ible airflow limitation.8 The relationship between the
pathological changes and pulmonary function is im-
portant. There have been several reports which inves-
tigated the relationship between the pathological
changes in specimens from transbronchial biopsies
and pulmonary functions or asthma symptoms.10,11
However, the relationship is not fully understood be-
cause of limited numbers of asthmatics receiving
transbronchial biopsy and the size of the transbron-
chial biopsy samples in which only the epithelum and
restricted submucosal areas can be analyzed.
According to previous papers, airway remodeling
was more prominent in the autopsy specimens than
in transbronchial samples because the majority of pa-
tients with fatal asthma had had severe asthmatic at-
tacks whereas patients with mild or moderate asthma
tend to accept transbronchial biopsy.11
EXAGGERATED EXTRACELLULAR MATRIX
DEPOSITION IN ASTHMATIC AIRWAYS
The repair process after tissue injury often includes a
fibrotic response. The chronic airway inflammation in
asthma causes epithelial injury and the subsequent,
repetitive repair process is thought to be responsible
for the thickening of the epithelial basement mem-
brane which has been observed as a characteristic
feature in asthma and is reported to be found even in
early asthma.12 The thickening of the basement mem-
brane observed by microscopy corresponds to the
deposition of extracellular matrix (ECM) at the
subepithelial space observed by electron microscopy
and is called subepithelial fibrosis.13,14 In addition,
Wilson reported the deposition of collagen not only in
the subepithelial space but also in the deeper submu-
cosal layer in asthmatics.15 The deposited ECM con-
sisted of type III and V collagen, laminin, tenascin
and fibronectin.15-18
One of the mechanisms of ECM deposition is
thought to be an imbalance between synthesis and
degradation. During transmigration through the
basement membrane, inflammatory cells such as
eosinophils produce and secrete matrix metallo-
proteinase-9 (MMP-9) capable of digesting type IV
collagen, which is one of the components of the base-
ment membrane.19 Over-production of tissue inhibi-
tors of matrix metalloproteinases 1 (TIMP-1), an in-
hibitor of MMP-9, causes deposition of ECM and
thickening of the basement membrane by inhibiting
the degradation of ECM.
TGF-β is known to be a cytokine that increases the
production of ECM. TGF-β is synthesized by a variety
of cells such as macrophages, lymphocytes, fibro-
blasts, airway epithelial cells, eosinophils, mast cells,
etc(Fig. 2).20-23 TGF-β also induces TIMP-1 expres-
sion and IL-13 augments TIMP-1 induction by TGF-β
suggesting that ECM deposition proceeds in asth-
matic airways in which Th2 cytokines are produced
continuously.24 In the airway, collagens have been
thought to be produced mainly by fibroblasts, and the
numbers of myofibroblasts in the submucosa are in-
creased in the asthmatic airway. In addition, connec-
tive tissue growth factor (CTGF) has attracted atten-
tion as a new growth factor which is directly involved
in the fibrotic response as a down-stream mediator of
TGF-β.25 Piao et al. demonstrated the up-regulation of
CTGF gene expression after allergen exposure in an
experimental asthma model with ovalbumin-sensi-
tized mice and an association between the level of
CTGF mRNA and collagen deposition in subepithelial
tissue (Figs. 3A, B).26 Recently, Kunzmann S et al. re-
ported that histamine induced CTGF production in
lung fibroblasts via H1 receptor suggesting allergic
inflammation tends to induce the fibrotic response
under the influence of histamine on fibroblasts in air-
ways.27
Fibrotic Airway Remodeling in Asthma
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Fig. 2 Quantitative analysis of TGFβ1 gene expression in 
bronchial tissue. The number of cels expressing TGFβ1 
mRNA in sections was scored. (This figure was from Ref 23, 
and modified.)
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Fig. 3 A; CTGF mRNA expression in pulmonary tissues in 
an experimental murine asthma model. The level of CTGF 
mRNA in pulmonary tissues from the mice exposed to aler
gen increased markedly compared with those exposed to sa
line, B; Relationship between the level of CTGF mRNA and 
the content of hydroxyproline in the lung. (This figure was 
from Ref 26, and modified.)
Since the thickening of the basement membrane in
asthmatic airways is easily observed and can be ana-
lyzed quantitatively in the tissue samples from trans-
bronchial biopsy, its relationship with pulmonary
functions such as FEV1.0 or airway hyperresponsive-
ness and asthma severity has been investigated
widely. Minshall et al. demonstrated a significant rela-
tionship between the thickness of the basement
membrane and airflow limitation, and furthermore, a
significant relationship between the thickness of the
basement membrane and the strength of TGF-β
mRNA expression in eosinophils.9 Smad7 is an inhibi-
tory protein against the intracellular signal transduc-
tion of TGF-β, and is thought to be a modulator of
TGF-β actions. Nakao et al. performed immunohisto-
chemistry for Smad7 in the bronchial tissues ob-
tained by transbronchial biopsy from asthmatics and
normal individuals, and compared its expression in
the airway of these two groups.28 They demonstrated
a significant reduction of Smad7 expression in asth-
matic airways compared to normals. To date, several
papers reported that the thickness of the basement
membrane had a negative relationship with FEV1%
(Fig. 4) and provocative dose of methacholine.29,30
An increase of the collagen content in airways may
alter the physical properties of the bronchial tree. In
fact, Ward et al. showed a negative relationship be-
tween the distensibility of the airway and the thick-
ness of the basement membrane.31 Furthermore, Mil-
anese et al. measured thickness of epithelial base-
ment membrane of bronchial tissues obtained by
transbronchial biopsy from patients with mild peren-
nial asthma, perennial allergic rhinitis, seasonal rhini-
tis and COPD. They revealed that the thickness of
the basement membrane in the patients with mild
perennial asthma and perennial allergic rhinitis was
significantly greater than in the patients with seasonal
rhinitis and COPD. In addition, the thickness of the
basement membrane in the patients with asthma
showed a positive relationship with the provocative
dose of methacholine.32 These results suggested that
Yamauchi K et al.
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Fig. 4 Corelation Rbm thickness and FEV1%. FEV1% 
was negatively corelated with Rbm thickness. (This figure 
was from Ref 30 and modified.)
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Fig. 5 Subepithelial colagen deposition in the peripheral 
airway of young and old asthmatics. (This figure was from 
Ref 36, and modified.)
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the reduction of elasticity in airway is associated with
the thickening of the basement membrane, which re-
sists the airway narrowing by smooth muscle contrac-
tion.
Deposited collagen makes the airway more rigid.
The rigidity may contribute to a protective effect
against airway smooth muscle (ASM) shortening or
airway narrowing. In animal models, airway wall
thickening,33 or the deposition of ECM such as colla-
gen or fibronectin in the airway wall after repeated al-
lergen exposure,34 was associated with attenuated
ASM shortening. Furthermore, Niimi et al. measured
the wall thickness of bronchi by helical computed to-
mography in patients with asthma and demonstrated
that the airway reactivity negatively correlated with
the airway wall thickness.35 Bai et al. reported that
older patients with fatal asthma had more muscle and
collagen deposition in the airway wall than younger
patients with fatal asthma(Fig. 5).36 In this paper, his-
tological analysis of the peripheral airway from
autopsy samples of asthmatic patients revealed that
the thickened airway wall consisted of smooth mus-
cle, fibrotic tissue and inflammatory cell infiltration.
The narrowing of the airway lumen suggested that
the fibrosis of the airway wall attenuated the smooth
muscle contraction by acting as a resistive force. The
fibrosis of the airway wall might protect against the
collapse of the airway lumen by an exaggerated con-
traction of the airway smooth muscle whose mass
was extraordinarily increased by hypertrophy and hy-
perplasia.
PHENOTYPES OF FIBROBLASTS INVOL-
VED IN AIRWAY WALL FIBROSIS
Bone marrow derived cells have been recognized to
play a critical role in tissue injury.37,38 Circulating fi-
brocytes can migrate to sites of wound-healing to
serve as a source for fibroblasts and myofibroblasts
that normally participate in the repair process.39
Hashimoto et al. demonstrated that bone marrow-
derived fibroblasts were involved in pulmonary fibro-
sis in rats treated with bleomycin. Their results sug-
gested the possibility that bone marrow-derived pre-
cursor cells could serve as a source for fibroblasts in
bleomycin-induced pulmonary fibrosis.40 Further-
more LPS induced lung injury recruited bone
marrow-derived progenitor cells which differentiated
into endothelial cells and epithelial cells in alveolar
tissue. These recruited bone marrow-derived pro-
genitor cells may play a critical role in tissue repair-
ing because suppression of the bone marrow-derived
progenitor cells induced emphysematous changes.41
A recent study demonstrated the existence of cir-
culating fibroblast-like cells in human beings.42
Schmidt et al. demonstrated that allergen exposure
induces the accumulation of fibrocyte-like cells in the
bronchial mucosa of patients with allergic asthma.
These cells were CD34-positive and expressed colla-
gen I and α-smooth muscle actin, and were localized
to areas of collagen deposition below the epithelium
(Fig. 6). They suggested that human circulating fibro-
cytes acquire the myofibroblast phenotype under in
vitro stimulation with fibrogenic cytokines that are
produced in exaggerated quantities in asthmatic air-
ways. These results suggest that circulating fibro-
cytes may function as myofibroblast precursors and
contribute to the pathogenesis of subepithelial fibro-
sis in asthma.43 Nihlberg K et al. detected more fibro-
cytes that were positive for CD34, CD45RO, procolla-
gen I, and α-smooth muscle actin in bronchial biop-
sies and BALF from mild asthmatic patients com-
pared to controls. They also showed the basement
membrane thickness could be correlated to the num-
ber of fibrocytes in tissue(Fig. 7).44 These results
Fibrotic Airway Remodeling in Asthma
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Fig. 6 Fibroblast-like cels in the airway wal of mice ex-
posed to alergen. Count of cels double-stained with the 
anti-CD34 and anti-procolagen I. ＊ p＜ 0.05 (This figure 
was from Ref 43, and modified.)
1 2 4 6 8
Weeks
PBS
OVA
0
10
20
30
40
50
C
D
34
 ＋
 P
ro
co
lla
ge
n 
I c
el
ls
 (
nu
m
be
r/
m
m
2)
＊
＊
＊
Fig. 7 Numbers of fibrocytes in bronchial tissues of asth
matics were counted and corelated (r＝0.711) to the thick
ness of basement membrane (μm). (This figure was from 
Ref 44, and modified.)
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Fig. 8 Absolute values of pulmonary resistance, central 
airway resistance, and peripheral resistance in normals and 
asthmatics. Total pulmonary resistance: white column, cen
tral  airway  resistance:  dashed  column,  peripheral 
resistance: gray column; Group A: asthmatics without air
flow limitation; Group B: asthmatics with airflow limitation. 
＊p＜0.01 (This figure was from Ref 47, and modified.)
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suggested that circulating fibrocytes could be one of
the critical therapeutic targets of airway remodeling
in asthma.
SITE OF REMODELING IN BRONCHIAL
TREE
The cellular components and their biological re-
sponses appear different in the proximal and distal
airways. Kotaru et al. suggested that at least two phe-
notypes of fibroblast exist in the lung and these phe-
notypic differences may partially explain the variable
responses to injury and repair between proximal air-
ways and distal lungparenchyma in asthma and
other respiratory diseases.45
Concerning pulmonary function, the site of ob-
struction in the bronchial tree in asthma was once
thought to be in the central airway because the total
area of the central airway is definitely smaller than
that of the peripheral airway. However, measurement
of the peripheral airway resistance with an antero-
grade catheter revealed that the peripheral airway re-
sistance in asthmatics was significantly higher than
that in normal subjects, suggesting that a pathologic
abnormality existed in the peripheral airway in
asthma.46,47 Furthermore, Ohrui et al. measured the
hyperresponsiveness to methacholine in the periph-
eral airway and demonstrated a relationship between
the hyperresponsiveness in the peripheral airway and
irreversible airflow limitation(Fig. 8).48 Pathological
studies on autopsy samples from patients who died of
asthma have shown the histological changes from the
central airway to the peripheral airway.49 However, it
is extremely difficult to obtain tissue of the peripheral
airway by bronchoscopy. Hamid et al. obtained lung
tissue from asthmatics who underwent an operation,
and analyzed the inflammatory cells in the peripheral
airway. They revealed that inflammatory changes in-
cluding eosinophil infiltration in the peripheral airway
(internal diameter <2 mm ) were more severe com-
pared with those in the central airway, suggesting
that the major site of the pathological abnormalities
in asthma is the peripheral airway.50 Bai et al. also de-
scribed smooth muscle hypertrophy and hyperplasia,
tissue fibrosis and inflammatory cell infiltration in the
peripheral airways of older patients who died from
with asthma.36
Peripheral airway is easily obstructed by smooth
muscle contraction in the absence of cartilage and by
mucous plugs. Previous reports revealed that asth-
Yamauchi K et al.
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Fig. 9 Duration of asthma according to asthma severity in 
the asthma outpatient clinic of Iwate medical University 
School of Medicine in 2005. (This figure was from Ref 59, 
and modified.)
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matics with peripheral airway obstruction tended to
have frequent asthma attacks.51 However, at present
there is little reliable information about airway re-
modeling in the peripheral airway.
THERAPY FOR AIRWAY REMODELING IN
ASTHMA
The development of airway remodeling has been re-
ported to be associated with severe asthma.52 While
some structural changes are reversible by therapy,
others are thought to be irreversible.53-55 For exam-
ple, goblet cell hyperplasia can be easily returned to
normal epithelium by sufficient inhaled corticosteroid
(ICS) therapy. In contrast, a thickened basement
membrane and airway wall fibrosis are relatively re-
sistant to ICS therapy. Irreversible airflow limitation
lowers the QOL of severe asthmatics. Airway remod-
eling in asthma is thought to cause impairments of
pulmonary function including irreversible airflow
limitation. Since chronic airway inflammation induces
airway remodeling in asthma, one of the effective
treatments at present is to control airway allergic in-
flammation. However, once airway remodeling has
been formed, it is hard to cure even if inhaled corti-
costeroid is used as described above in the case of
subepthelial fibrosis. As we know, almost all patients
with early asthma categorized as mild asthma, but
some of these patients show increased severity over
time. However, the factors that aggravate the severity
of asthma have not been elucidated clearly.
Since, as described above, airway remodeling in
the peripheral airway is critical for the pulmonary
function and severity of asthma, one of the important
targets of asthma therapy is the peripheral airway. To
date, it has been thought that particles of inhaled cor-
ticosteroid hardly reached to the peripheral airway.
Recently, new types of inhaled corticosteroids, such
as HFA-beclomethasone or HFA-cyclesonid, showed
high deposition on peripheral airway and lung paren-
chyma because the particles are ultra-fine. Hauber et
al. reported that eosinophilic inflammation in the pe-
ripheral airway was suppressed by HFA-flunisolide in
asthmatics.56 Bergeron et al. showed a reduction of
the smooth muscle area and an improvement of pe-
ripheral airflow limitation with HFA-flunisolide in pa-
tients with mild to moderate asthma, suggesting that
treatment with ICS, the particle of which are smaller
particle sized, would be effective to treat airway in-
flammation and remodeling in the peripheral air-
way.57
Since some components of airway remodeling are
resistant to ICS therapy, early intervention is thought
to be an important strategy to prevent airway remod-
eling. Haahtela et al. described that a delay in starting
ICS therapy induced irreversible airflow limitation
which was thought to be caused by airway remodel-
ing.58 A large number of patients with severe asthma
showing irreversible airflow limitation had a signifi-
cantly longer duration of asthma compared to those
with mildmoderate asthma. We can speculate that a
considerable number of the patients with severe
asthma had not received appropriate asthma therapy
including ICS in the early stage of asthma. Since
most clinicians started to adopt ICS therapy for
asthma in Japan in the 1990’s, we assume that many
patients did not receive ICS therapy early enough in
their treatment before the 1990’s, which impaired
their pulmonary function, at least in part by airway re-
modeling, resulting in a worsening of their asthma se-
verity. As a matter of fact, FEV1% predicted is signifi-
cantly lower in Japanese patients with severe asthma
compared to those with mildmoderate asthma, and
the asthma duration among Japanese patients with
severe asthma was significantly longer (Fig. 9).59 On
the other hand, a significant reduction in the ratio of
severe asthma was revealed in a 10-year study of a
Japanese population of newly diagnosed as asthma,
that received standard therapy for asthma including
ICS (Figs. 10A, B).
Recently, Hendersen et al. reported that montelu-
kast, a leukotriene receptor antagonist, suppressed
subepithelial fibrosis and smooth muscle hypertro-
phy in a murine asthma model exposed to antigen.
Furthermore, they also demonstrated that montelu-
kast ameliorated the already formed airway remodel-
ing in murine asthma model after one month expo-
sure to allergen.60,61 Leukotriene C4 and D4 are
thought to play an important role in fibroblast prolif-
eration and ECS production. In this regard, the ef-
fects of montelukast on remodeling in human airway
need to be evaluated.
In summary, at present early introduction of ICS to
newly diagnosed asthmatics may be a useful and
practical therapeutic strategy to prevent progress of
Fibrotic Airway Remodeling in Asthma
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Fig. 10 A; Distribution of asthmatics according to asthma 
severity in the asthma outpatient clinic of Iwate medical Uni
versity School of Medicine in 2005. The ratio of the patients 
with severe asthma exceeded more than 30% despite sufi
cient therapy with high dose ICS, B; Distribution of asthma 
severity of asthmatics who were newly diagnosed as 
asthmatic. No severe asthma was recorded in the newly di
agnosed asthma from 1995 to 2005. (This figure was from 
Ref 59, and modified.)
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